Institute of Hematology & Blood Diseases Hospital, China: clinical-trial pipeline
Institute of Hematology & Blood Diseases Hospital, China is the sponsor of 401 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 274 are not yet finished and 15 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials274
Phase 2/3 and 319
Countries2
New in 90 days15
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 147 |
| Not applicable | 108 |
| Phase 1 | 53 |
| Phase 1/2 | 34 |
| Early phase 1 | 24 |
| Phase 4 | 16 |
| Phase 3 | 12 |
| Phase 2/3 | 7 |
Trials by status
| Status | Trials |
|---|---|
| Recruiting | 155 |
| Not yet recruiting | 99 |
| Unknown | 64 |
| Completed | 41 |
| Active, not recruiting | 20 |
| Terminated | 12 |
| Withdrawn or not authorised | 10 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 190 |
| Haematology | 123 |
| Immunology and rheumatology | 77 |
| Cardiovascular | 53 |
| Infectious disease and vaccines | 22 |
| Rare and genetic diseases | 14 |
| Gastroenterology and liver | 5 |
| Musculoskeletal | 4 |
| Dermatology | 3 |
| Respiratory | 3 |
| Neurology | 2 |
| Nephrology and urology | 1 |
Countries
| Country | Trials |
|---|---|
| China | 322 |
| Hong Kong SAR China | 4 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-09-30 | New trial posted | Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pedia… |
| 2026-09-30 | New trial posted | Nutritional Intervention for Patients Undergoing Allogeneic Hematopoietic Stem Cell Trans… |
| 2026-09-25 | New trial posted | Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL |
| 2026-09-23 | New trial posted | Human Albumin Combined With Plasma Exchange for Frailty Intervention |
| 2026-09-21 | New trial posted | Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome… |
| 2026-09-21 | New trial posted | CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple… |
| 2026-09-18 | New trial posted | F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients Wit… |
| 2026-09-18 | New trial posted | Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfi… |
| 2026-09-11 | New trial posted | Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia |
| 2026-09-10 | New trial posted | HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Di… |
| 2026-09-09 | New trial posted | CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma |
| 2026-08-27 | New trial posted | A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07126782 | The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT | Early phase 1 | Recruiting | China |
| NCT06481241 | Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL | Not applicable | Recruiting | China |
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | Phase 3 | Recruiting | China |
| NCT05979363 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in T… | Phase 2 | Recruiting | China |
| NCT07297576 | Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantat… | Not applicable | Recruiting | China |
| NCT07461116 | Adverse Effects of ATG/ALG Therapy in Aplastic Anemia | Not applicable | Recruiting | China |
| NCT03980002 | A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With… | Phase 2 | Recruiting | China |
| NCT07212322 | A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases | Not applicable | Not yet recruiting | China |
| NCT06792630 | A Study of the Effect of Laughter Therapy on the Mental Health and Quality of Survival of Hematopoietic Stem… | Not applicable | Not yet recruiting | |
| NCT06744556 | HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | Phase 2 | Active, not recruiting | China |
| NCT07539662 | Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Not applicable | Recruiting | China |
| NCT06238908 | Safety and Efficacy Study of NGGT003 in Hemophilia A Patients | Early phase 1 | Recruiting | China |
| NCT05214391 | A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia | Phase 2 | Recruiting | China |
| NCT05888870 | ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibi… | Phase 4 | Recruiting | China |
| NCT07539610 | Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted T… | Phase 1 | Not yet recruiting | China |
| NCT07299149 | Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma | Phase 2 | Recruiting | China |
| NCT06635681 | Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML | Phase 2 | Recruiting | China |
| NCT07836127 | Human Albumin Combined With Plasma Exchange for Frailty Intervention | Not applicable | Not yet recruiting | China |
| NCT07539818 | Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML | Phase 3 | Not yet recruiting | |
| NCT06490562 | Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI | Not applicable | Not yet recruiting | |
| NCT07322159 | IASO206 in Patients With Relapsed/Refractory Multiple Myeloma | Early phase 1 | Not yet recruiting | |
| NCT06254560 | Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness | Phase 2 | Recruiting | China |
| NCT06611839 | Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML | Phase 1/2 | Recruiting | China |
| NCT06199089 | A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of… | Phase 2 | Active, not recruiting | China |
| NCT07010237 | Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia | Phase 2 | Recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Institute of Hematology & Blood Diseases Hospital, China clinical trials: 274 open, 19 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/institute-of-hematology-blood-diseases-hospital-china/, data as of 2026-10-25.